Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
“Alongside our development of SP-26, our novel time-release topical formulation of ketamine, we are beginning to explore an additional option for treating fibromyalgia using ketamine-loaded implants. The outcome of this research will provide additional information and data for our ongoing studies of ketamine treatments for fibromyalgia and other chronic pain indications.”
Eric Weisblum, Chief Executive Officer of Silo Pharma
Fibromyalgia is a chronic condition causing widespread musculoskeletal pain accompanied by memory issues, sleep problems, and fatigue. The disorder affects about four million American adults, or about 2% of the adult population, and its treatment market is projected to grow at a compound annual growth rate of over 9% in the 2020-2027 period.1
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry.